<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41788">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01810224</url>
  </required_header>
  <id_info>
    <org_study_id>GRAFFITI</org_study_id>
    <nct_id>NCT01810224</nct_id>
  </id_info>
  <brief_title>Graft Patency After FFR-guided Versus Angio-guided CABG (GRAFFITI) Trial</brief_title>
  <acronym>GRAFFITI</acronym>
  <official_title>Graft Patency After FFR-guided Versus Angio-guided CABG: a Prospective, Multicenter, Multinational, Randomized (1:1) Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Onze Lieve Vrouw  Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Onze Lieve Vrouw  Hospital</source>
  <oversight_info>
    <authority>Belgium: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is prospective, randomized, multicenter, multinational, randomized (1:1) study. The aim
      of this study is to assess the importance of functional assessment of coronary artery
      disease prior to bypass surgery. In particular, an FFR-guided strategy will be compared to
      the traditional Angio-guided strategy in the guidance of surgical revascularization by
      aorto-coronary bypass grafting.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Rate of occluded bypass grafts</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>a) Lenght of hospital stay; b) Changes in surgical strategy: i.e. open-chest surgery vs. mini-thoracotomy; extensive surgery versus minimal invasive approaches.</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 3-4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">206</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Angio-guided arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In this arm will be included the patient randomized to a Angiography-guided surgical revascularization strategy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FFR-guided arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm will be included the patient randomized to a FFR-guided surgical revascularization strategy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical revascularization</intervention_name>
    <description>The final intervention (surgical revascularization) will be the same for both arms.</description>
    <arm_group_label>Angio-guided arm</arm_group_label>
    <arm_group_label>FFR-guided arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with stable angina, unstable angina or NSTEMI candidate to CABG

          -  Significant LAD and/or LM lesion - proved by FFR or Angiography AND

          -  At least one more, angiographycally intermediate lesion

        Exclusion Criteria:

          -  Significant valvular disease with indication to surgical replacement

          -  Severe left ventricular dysfunction (EF&lt;35%)

          -  Acute STEMI

          -  Atrial fibrillation, if Maze procedure is planned
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emanuele Barbato, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular Center Aalst, OLV Hospital, Aalst (Belgium)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emanuele Barbato, MD, PhD</last_name>
    <email>emanuele.barbato@olvz-aalst.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cardiovascular Center Aalst OLV Hospital</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Emanuele Barbato, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernard De Bruyne, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gabor Toth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine and Cardiology, University Hospital Brno</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Petr Kala, MD</last_name>
      <email>kalapetr7@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Petr Kala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hungarian Institute of Cardiology</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zsolt Piroth</last_name>
      <email>piroth@freemail.hu</email>
    </contact>
    <investigator>
      <last_name>Zsolt Piroth, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Hungary</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 11, 2013</lastchanged_date>
  <firstreceived_date>March 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Onze Lieve Vrouw  Hospital</investigator_affiliation>
    <investigator_full_name>Emanuele Barbato</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
